• 5 min read
• Published on 25 July 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Pharma
Let’s be honest, the market has felt a bit unhinged lately. One minute, everyone is piling into some tech firm that promises to revolutionise how we order toast, and the next, it’s all gone pear shaped. It’s exhausting. Amidst this chaos, I find myself drawn to industries grounded in something a little more, well, real. And what’s more real than the simple, inescapable fact that people get sick?
You don’t stop needing a doctor just because the economy takes a tumble. You don’t cancel your prescription because of geopolitical tensions. This fundamental, almost grim, reality is what makes the pharmaceutical sector so compelling to me. It’s what investment types call a ‘defensive’ play, which is a rather dry term for an industry built on one of life’s certainties. While other sectors are chasing fleeting trends, healthcare is quietly serving a demand that never disappears. The numbers back this up, with projections suggesting the global pharmaceutical market could reach a staggering $1.9 trillion by 2027. It’s a powerful, underlying current in an otherwise choppy sea.
View the full Basket:Pharma
Now, I know what you’re thinking. Defensive sounds dreadfully boring. It conjures images of slow, plodding companies churning out the same old pills for decades. And while there’s an element of that stability, it’s only half the story. The very same industry that offers this bedrock of consistency can also produce some of the most explosive growth stories you’ll ever see.
Think back to the pandemic. While most of us were learning to bake sourdough, companies like Moderna went from being relative unknowns to global saviours, and their stock prices reflected that astonishing transformation. It was a stark reminder that this sector isn’t just about managing chronic conditions, it’s about curing them. Giants like Johnson & Johnson embody this duality perfectly. They offer the steady reliability of consumer goods alongside the high-stakes, high-reward world of pharmaceutical research. It’s a rare combination of a safety net and a potential rocket launch, all in one.
View the full Basket:Pharma
Investing in this space isn’t for the faint of heart, I’ll grant you that. The path from a promising molecule in a lab to a drug on pharmacy shelves is long and fraught with peril. For every successful treatment, countless others fail during clinical trials, taking investor hopes and capital with them. Then there’s the dreaded ‘patent cliff’, where a blockbuster drug loses its protection and suddenly faces a flood of cheap generic competition. It can gut a company’s revenue almost overnight.
This is precisely why putting all your eggs in one biotech basket is a fool’s errand. The key, as with most sensible investing, is diversification. You want exposure to a range of companies at different stages, with different specialities. Spreading your risk across established leaders and innovative challengers is crucial. This is why looking at a curated collection, like the Pharma Giants basket, can make a lot of sense. It helps smooth out the terrifying bumps that come from backing a single horse in this very high-stakes race.
View the full Basket:Pharma
If you need one final, compelling reason to consider this sector, it’s demographics. We’re all getting older. It’s not a cheerful thought, I admit, but it’s a powerful economic force. Aging populations in the developed world create a structural tailwind for healthcare that is almost impossible to stop. Older people simply require more medical care, more treatments, and more pharmaceuticals.
This isn’t a short term trend that will fizzle out next quarter. It’s a slow-moving, multi-decade shift that provides a solid foundation for long term growth. When you combine this with rising incomes in emerging markets, which are unlocking access to modern medicine for billions of people, the demand picture looks incredibly robust. In a world of fads and fashions, investing in a sector driven by the fundamental, unglamorous process of human aging might just be the most pragmatic move you can make.
View the full Basket:Pharma
View the full Basket:Pharma
View the full Basket:Pharma
View the full Basket:Pharma
View the full Basket:Pharma
View the full Basket:Pharma
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article